What is the current macular degeneration drug pipeline market size?

The macular degeneration drug pipeline market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the macular degeneration drug pipeline market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the macular degeneration drug pipeline market?

Key drivers include rising prevalence, technological advancements, and expanding treatment options.

What challenges does the macular degeneration drug pipeline market face?

Challenges include high development costs, regulatory hurdles, and intense competition.

Which regions are leading the macular degeneration drug pipeline market?

North America and Europe are leading the market due to high healthcare expenditure.

Who are the top companies in the macular degeneration drug pipeline market?

Top companies include Novartis, Roche, and Regeneron, which are investing heavily in research.

What future opportunities exist in the macular degeneration drug pipeline market?

Future opportunities include emerging technologies, gene therapies, and combination treatments.

How is technology impacting the macular degeneration drug pipeline market?

Technology is driving innovation, improving diagnosis, and enhancing treatment outcomes.

What is the regulatory landscape for the macular degeneration drug pipeline market?

The regulatory landscape is evolving, with a focus on safety, efficacy, and patient access.

What is the future outlook for the macular degeneration drug pipeline market?

The future outlook is promising, with a growing market size and increasing investment.

macular degeneration drug pipeline Growth Trends & Opportunity Analysis 2033

macular degeneration drug pipeline by Application (Hospital, Research Institute, Commercial, Other), by Types (Gene therapy, Small molecules, Stem cell therapy, Gene therapies) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

macular degeneration drug pipeline Market Size | CAGR 0.065 Forecast 2033

macular degeneration drug pipeline Growth Trends & Opportunity Analysis 2033

macular degeneration drug pipeline by Application (Hospital, Research Institute, Commercial, Other), by Types (Gene therapy, Small molecules, Stem cell therapy, Gene therapies) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 0.065%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

macular degeneration drug pipeline Market Overview

The macular degeneration drug pipeline market refers to the industry involved in the development and commercialization of therapeutic products for the treatment of macular degeneration, a condition that causes vision loss. As the global population ages, the relevance of this market continues to grow. The macular degeneration drug pipeline market size is estimated to be around $12.5 billion in 2025, with a growth outlook that is promising due to the increasing prevalence of age-related macular degeneration. The market forecast suggests a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2026 to 2033, driven by advancements in ophthalmic treatments and an expanding patient population. The industry expansion is expected to be fueled by technological innovations, regulatory approvals, and changing consumer behavior.

Loading chart…

The macular degeneration drug pipeline market is driven by key forces such as technology shifts towards more targeted and effective treatments, regulatory approvals that facilitate the entry of new products, and competitive intensity that encourages innovation and investment. The largest region in this market is North America, while the fastest-growing region is Asia-Pacific, driven by an increasing geriatric population and improving healthcare infrastructure. As the market continues to evolve, it is essential for industry stakeholders to stay informed about the latest developments and trends to make strategic decisions and capitalize on emerging opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	12.41 billion
Growth rate	CAGR of 0.065% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Amgen; Roche; Adverum Biotechnologies; AsclepiX Therapeutics; Bioeq AG; Sinocelltech; RemeGen; Grifols, S.A.; Kyowa Kirin; EyePoint Pharmaceutical; IVERIC Bio; Kodiak Sciences; Ribomic; Lineage Cell Therapeutics; Graybug Vision; CHABiotech; Shanghai Henlius Biotech; Bio-Thera Solutions; Alteogen; Outlook Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The macular degeneration drug pipeline market is witnessing significant transformations, driven by various factors. The market dynamics are crucial in understanding the current and future growth forecast of the macular degeneration drug pipeline market size.

Growth Drivers2 items

Increasing prevalence of age-related macular degeneration is fueling the demand for innovative treatments, thereby driving the growth of the macular degeneration drug pipeline market.

Advancements in ophthalmic technologies, such as gene therapies and stem cell therapies, are expanding the treatment landscape and contributing to the growth forecast of the market.

Restraints2 items

High development costs and regulatory hurdles are limiting the entry of new players in the macular degeneration drug pipeline market, thus restraining its growth.

Stringent clinical trial requirements and patent protection issues are further challenging the development of novel therapies, affecting the macular degeneration drug pipeline market size.

Opportunities2 items

Partnerships and collaborations between pharmaceutical companies, research institutions, and biotechnology firms are creating new opportunities for the development of innovative treatments, driving the growth forecast of the macular degeneration drug pipeline market.

Emerging markets, particularly in Asia-Pacific, offer significant growth potential due to an increasing geriatric population and rising awareness about ophthalmic diseases, contributing to the expansion of the macular degeneration drug pipeline market size.

Challenges2 items

The macular degeneration drug pipeline market faces challenges in terms of pricing and reimbursement, as high-cost treatments may not be accessible to all patients, affecting the market's growth forecast.

Ensuring supply chain efficiency and managing manufacturing complexities are crucial in maintaining a stable and consistent supply of treatments, which is essential for the macular degeneration drug pipeline market size to grow.

Market Segmentation

Loading chart…

The macular degeneration drug pipeline market can be segmented based on application, which refers to the specific use of the drugs in treating various stages and types of macular degeneration. This segmentation is crucial in understanding the macular degeneration drug pipeline segmentation as it helps in identifying the target audience and tailoring the treatment to their specific needs.

The types of macular degeneration drugs can be further categorized into subtypes, including wet age-related macular degeneration (AMD) and dry AMD. Wet AMD is characterized by the presence of abnormal blood vessels under the macula, while dry AMD is marked by the accumulation of waste material in the retina. Understanding these subtypes is essential in developing effective treatment strategies and contributing to the overall macular degeneration drug pipeline market size.

macular degeneration drug pipeline Segmentation Breakdown10 items

Application

Hospital

Research Institute

Commercial

Other

Types

Gene therapy

Small molecules

Stem cell therapy

Gene therapies

Regional Insights

Loading chart…

The macular degeneration drug pipeline market is expected to experience significant growth, driven by various regional factors. North America is the largest region, accounting for approximately 40% of the market, driven by high adoption rates of novel therapies, favorable policies supporting research and development, and substantial investments in healthcare infrastructure. Europe is the second-largest region, with a share of around 30%, driven by established healthcare ecosystems, mature infrastructure, and high demand for innovative treatments.

The fastest-growing region is Asia Pacific, with a projected regional forecast of 10% annual growth, driven by increasing demographics with rising life expectancy, expanding healthcare infrastructure, and growing investments in research and development. Latin America and Middle East & Africa are also expected to experience growth, with shares of around 15% and 15%, respectively, driven by improving healthcare access, growing awareness of macular degeneration, and rising demand for effective treatments. Key drivers for each region include adoption of new technologies, policies supporting healthcare development, and investments in research and infrastructure.

Competitive Landscape

The macular degeneration drug pipeline market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals, which shape the macular degeneration drug pipeline competitive landscape. Global players focus on premium pricing and robust distribution networks, while local companies emphasize affordable pricing and regional partnerships.

Common strategies among key players involve M&A, partnerships, product launches, expansion, R&D, and localization. Companies differentiate themselves through technology, service models, channel strength, customization, and cost advantages. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. To stay competitive, companies must strategically navigate these factors and adapt to changing market conditions.

Amgen: regional expansion

Roche: innovation pipeline

Adverum Biotechnologies: premium pricing

AsclepiX Therapeutics: local manufacturing

Bioeq AG: OEM tie-ups

Sinocelltech: vertical integration

Key macular degeneration drug pipeline Companies20 items

Amgen

Roche

Adverum Biotechnologies

AsclepiX Therapeutics

Bioeq AG

Sinocelltech

RemeGen

Grifols, S.A.

Kyowa Kirin

EyePoint Pharmaceutical

IVERIC Bio

Kodiak Sciences

Ribomic

Lineage Cell Therapeutics

Graybug Vision

CHABiotech

Shanghai Henlius Biotech

Bio-Thera Solutions

Alteogen

Outlook Therapeutics

Market Ecosystem

The macular degeneration drug pipeline ecosystem encompasses a complex network of participants, spanning from upstream technology providers to downstream end users. This ecosystem can be broadly divided into three stages: upstream, where raw materials and technologies are developed; midstream, where these inputs are integrated into drugs; and downstream, where the final products are distributed to end users. The value chain analysis of this ecosystem reveals how value is created and captured at each stage, from research and development to commercialization and patient treatment.

Raw material suppliers — providing active pharmaceutical ingredients

Technology providers — developing innovative drug delivery systems

OEMs/manufacturers — producing finished pharmaceutical products

System integrators — overseeing clinical trials and regulatory approvals

Distributors/channel partners — delivering products to healthcare providers

Service providers — offering patient support and education programs

Regulators/standards bodies — establishing and enforcing safety and efficacy standards

The flow of value through the macular degeneration drug pipeline ecosystem is influenced by various control points, including regulatory approvals and reimbursement decisions. Dependency risks, such as input constraints and standards compliance, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the relationships between participants. The ecosystem's structure and dynamics can differ by region, with varying levels of access to healthcare services and innovative treatments. Understanding these factors is essential for navigating the complex macular degeneration drug pipeline ecosystem.

Recent Industry Insights

The macular degeneration drug pipeline industry trends have witnessed significant developments in the last 12-18 months. Notable partnerships, such as collaborations between pharmaceutical companies and research institutions, have been formed to accelerate the discovery of novel treatments. Furthermore, there have been several mergers and acquisitions, product launches, and regulatory changes that have reshaped the industry landscape. The shift in consumer trends towards more personalized and targeted therapies has also driven innovation in the macular degeneration drug pipeline industry.

In addition, the industry has seen substantial funding rounds and expansions, with many companies investing heavily in research and development. These advancements are expected to propel the growth of the macular degeneration drug pipeline industry, offering new hope for patients and driving progress in the field of ophthalmology. As the industry continues to evolve, it is likely that we will see even more exciting developments in the coming months and years, further solidifying the importance of staying up-to-date on the latest macular degeneration drug pipeline industry trends.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the macular degeneration drug pipeline market. The market attractiveness is moderate, driven by the increasing prevalence of age-related macular degeneration and the need for effective treatments. The competitive intensity is high, with several pharmaceutical companies investing heavily in research and development. The long-term outlook for the macular degeneration drug pipeline market outlook is promising, with a growing demand for innovative therapies. However, the innovation landscape is rapidly evolving, and companies must stay ahead of the curve to remain competitive.

The demand-supply balance is expected to be stable, with a steady stream of new products entering the market. Key risk factors include regulatory hurdles, patent expirations, and changing patient demographics. Despite these challenges, the market is poised for growth, driven by advances in gene therapy and other innovative approaches. Overall, the macular degeneration drug pipeline market presents opportunities for companies that can navigate the complex landscape and deliver effective treatments to patients in need.

11 items

1. Executive Summary

2. macular degeneration drug pipeline Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global macular degeneration drug pipeline Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global macular degeneration drug pipeline Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Research Institute

6.1.3. Commercial

6.1.4. Other

6.2. Global macular degeneration drug pipeline Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Gene therapy

6.2.2. Small molecules

6.2.3. Stem cell therapy

6.2.4. Gene therapies

6.3. Global macular degeneration drug pipeline Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global macular degeneration drug pipeline Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global macular degeneration drug pipeline Market by: Regions (Value)

8. Global macular degeneration drug pipeline Market Competition by Key Manufacturers

8.1. Global macular degeneration drug pipeline Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global macular degeneration drug pipeline: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Adverum Biotechnologies

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. AsclepiX Therapeutics

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Bioeq AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Sinocelltech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. RemeGen

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Grifols, S.A.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Kyowa Kirin

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. EyePoint Pharmaceutical

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. IVERIC Bio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Kodiak Sciences

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Ribomic

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Lineage Cell Therapeutics

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Graybug Vision

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. CHABiotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Shanghai Henlius Biotech

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Bio-Thera Solutions

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Alteogen

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Outlook Therapeutics

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global macular degeneration drug pipeline Market

Figure 4: Global macular degeneration drug pipeline Market: Drivers

Figure 5: Global macular degeneration drug pipeline Market: Challenges

Figure 6: Global macular degeneration drug pipeline Market: Trends

Figure 7: Global macular degeneration drug pipeline Market: Opportunity

Figure 8: Global macular degeneration drug pipeline Market: Restraint

Figure 9: Global macular degeneration drug pipeline Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global macular degeneration drug pipeline Market Value (USD Million) By Region

Figure 15: Global macular degeneration drug pipeline Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global macular degeneration drug pipeline Market Value (USD Million) By Region

Figure 23: Global macular degeneration drug pipeline Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global macular degeneration drug pipeline Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global macular degeneration drug pipeline Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global macular degeneration drug pipeline Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global macular degeneration drug pipeline Market Value (USD Million) By Region

Table 10: Global macular degeneration drug pipeline Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global macular degeneration drug pipeline Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global macular degeneration drug pipeline Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global macular degeneration drug pipeline Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Basic Information And Sales Area

Table 31: Amgen. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Adverum Biotechnologies Basic Information And Sales Area

Table 35: Adverum Biotechnologies. Products Portfolio

Table 36: AsclepiX Therapeutics Basic Information And Sales Area

Table 37: AsclepiX Therapeutics. Products Portfolio

Table 38: Bioeq AG Basic Information And Sales Area

Table 39: Bioeq AG. Products Portfolio

Table 40: Sinocelltech Basic Information And Sales Area

Table 41: Sinocelltech. Products Portfolio

Table 42: RemeGen Basic Information And Sales Area

Table 43: RemeGen. Products Portfolio

Table 44: Grifols, S.A. Basic Information And Sales Area

Table 45: Grifols, S.A.. Products Portfolio

Table 46: Kyowa Kirin Basic Information And Sales Area

Table 47: Kyowa Kirin. Products Portfolio

Table 48: EyePoint Pharmaceutical Basic Information And Sales Area

Table 49: EyePoint Pharmaceutical. Products Portfolio

Table 50: IVERIC Bio Basic Information And Sales Area

Table 51: IVERIC Bio. Products Portfolio

Table 52: Kodiak Sciences Basic Information And Sales Area

Table 53: Kodiak Sciences. Products Portfolio

Table 54: Ribomic Basic Information And Sales Area

Table 55: Ribomic. Products Portfolio

Table 56: Lineage Cell Therapeutics Basic Information And Sales Area

Table 57: Lineage Cell Therapeutics. Products Portfolio

Table 58: Graybug Vision Basic Information And Sales Area

Table 59: Graybug Vision. Products Portfolio

Table 60: CHABiotech Basic Information And Sales Area

Table 61: CHABiotech. Products Portfolio

Table 62: Shanghai Henlius Biotech Basic Information And Sales Area

Table 63: Shanghai Henlius Biotech. Products Portfolio

Table 64: Bio-Thera Solutions Basic Information And Sales Area

Table 65: Bio-Thera Solutions. Products Portfolio

Table 66: Alteogen Basic Information And Sales Area

Table 67: Alteogen. Products Portfolio

Table 68: Outlook Therapeutics Basic Information And Sales Area

Table 69: Outlook Therapeutics. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global macular degeneration drug pipeline Market Value (USD Million) By Region

Table 75: Global macular degeneration drug pipeline Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

macular degeneration drug pipeline Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	12.41 billion
Growth rate	CAGR of 0.065% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Amgen; Roche; Adverum Biotechnologies; AsclepiX Therapeutics; Bioeq AG; Sinocelltech; RemeGen; Grifols, S.A.; Kyowa Kirin; EyePoint Pharmaceutical; IVERIC Bio; Kodiak Sciences; Ribomic; Lineage Cell Therapeutics; Graybug Vision; CHABiotech; Shanghai Henlius Biotech; Bio-Thera Solutions; Alteogen; Outlook Therapeutics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options